Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE008 (KOR) (Dr. Kim)
· consented 2022-10-25
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Decreased appetite — outcome: UNKNOWN; onset 2022-11-22 (study day 17); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-12-24 (study day 49); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-01-07 (study day 63); relationship: N
moderate
assessed
2026-08-18
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-01-22 (study day 78); relationship: N
mild
assessed
2026-08-18
Grade 1 Vomiting — outcome: UNKNOWN; onset 2023-02-07 (study day 94); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.